Optimal and suboptimal protocols for a mathematical model for tumor anti-angiogenesis in combination with chemotherapy.

We consider the problem of minimizing the tumor volume with a priori given amounts of anti-angiogenic and cytotoxic agents. For one underlying mathematical model, optimal and suboptimal solutions are given for four versions of this problem: the case when only anti-angiogenic agents are administered, combination treatment with a cytotoxic agent, and when a standard linear pharmacokinetic equation for the anti-angiogenic agent is added to each of these models. It is shown that the solutions to the more complex models naturally build upon the simplified versions. This gives credence to a modeling approach that starts with the analysis of simplified models and then adds increasingly more complex and medically relevant features. Furthermore, for each of the problem formulations considered here, there exist excellent simple piecewise constant controls with a small number of switchings that virtually replicate the optimal values for the objective.

[1]  Urszula Ledzewicz,et al.  Optimal controls for a model with pharmacokinetics maximizing bone marrow in cancer chemotherapy. , 2007, Mathematical biosciences.

[2]  Richard Bellman,et al.  Introduction to the mathematical theory of control processes , 1967 .

[3]  P. Hahnfeldt,et al.  Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. , 1999, Cancer research.

[4]  Alberto d'Onofrio,et al.  Rapidly acting antitumoral antiangiogenic therapies. , 2007, Physical review. E, Statistical, nonlinear, and soft matter physics.

[5]  M. I. Zelikin,et al.  Theory of Chattering Control: with applications to Astronautics, Robotics, Economics, and Engineering , 1994 .

[6]  U. Ledzewicz,et al.  The influence of pk/pd on the structure of optimal controls in cancer chemotherapy models. , 2005, Mathematical biosciences and engineering : MBE.

[7]  A. Świerniak,et al.  Direct and indirect control of cancer populations , 2008 .

[8]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[9]  J. Folkman,et al.  Anti‐Angiogenesis: New Concept for Therapy of Solid Tumors , 1972, Annals of surgery.

[10]  Urszula Ledzewicz,et al.  OPTIMAL CONTROL FOR A CLASS OF COMPARTMENTAL MODELS IN CANCER CHEMOTHERAPY , 2003 .

[11]  J. Folkman,et al.  Angiogenesis Inhibitors Generated by Tumors , 1995, Molecular medicine.

[12]  Urszula Ledzewicz,et al.  Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis. , 2008, Journal of theoretical biology.

[13]  M. Chyba,et al.  Singular Trajectories and Their Role in Control Theory , 2003, IEEE Transactions on Automatic Control.

[14]  Shay Soker,et al.  VEGF/VPF: The angiogenesis factor found? , 1993, Current Biology.

[15]  Urszula Ledzewicz,et al.  No . 4 B Singular controls and chattering arcs in optimal control problems arising in biomedicine , 2010 .

[16]  R. Kerbel Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.

[17]  H. Maurer,et al.  Optimization methods for the verification of second order sufficient conditions for bang–bang controls , 2005 .

[18]  Urszula Ledzewicz,et al.  ANALYSIS OF A CELL-CYCLE SPECIFIC MODEL FOR CANCER CHEMOTHERAPY , 2002 .

[19]  Urszula Ledzewicz,et al.  Optimal Bang-Bang Controls for a Two-Compartment Model in Cancer Chemotherapy , 2002 .

[20]  H. Schättler,et al.  A Synthesis of Optimal Controls for a Model of Tumor Growth under Angiogenic Inhibitors , 2005, Proceedings of the 44th IEEE Conference on Decision and Control.

[21]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[22]  H. Schättler,et al.  On optimal delivery of combination therapy for tumors. , 2009, Mathematical biosciences.

[23]  R. Kerbel A cancer therapy resistant to resistance , 1997, Nature.

[24]  M. I. Zelikin,et al.  The Ubiquity of Fuller’s Phenomenon , 1994 .

[25]  Alberto Gandolfi,et al.  A family of models of angiogenesis and anti-angiogenesis anti-cancer therapy. , 2008, Mathematical medicine and biology : a journal of the IMA.

[26]  Urszula Ledzewicz,et al.  AntiAngiogenic Therapy in Cancer Treatment as an Optimal Control Problem , 2007, SIAM J. Control. Optim..

[27]  Urszula Ledzewicz,et al.  Bang-bang and singular controls in a mathematical model for combined anti-angiogenic and chemotherapy treatments , 2009, Proceedings of the 48h IEEE Conference on Decision and Control (CDC) held jointly with 2009 28th Chinese Control Conference.

[28]  Alberto Gandolfi,et al.  Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999). , 2004, Mathematical biosciences.

[29]  L. Wein,et al.  Optimal scheduling of radiotherapy and angiogenic inhibitors , 2003, Bulletin of mathematical biology.

[30]  D. Wishart Introduction to the Mathematical Theory of Control Processes. Volume 1—Linear Equations and Quadratic Criteria , 1969 .

[31]  Urszula Ledzewicz,et al.  Scheduling of angiogenic inhibitors for Gompertzian and logistic tumor growth models , 2009 .

[32]  Urszula Ledzewicz,et al.  Robustness of optimal controls for a class of mathematical models for tumor anti-angiogenesis. , 2011, Mathematical biosciences and engineering : MBE.

[33]  U. Ledzewicz,et al.  ANTI-ANGIOGENIC THERAPY IN CANCER TREATMENT AS AN OPTIMAL CONTROL PROBLEM , 2007 .